ERBB2 and ovarian cancer: A phase I trial combining carboplatin and lapatinib (Tykerb, Tyverb, Glaxo SmithKline, plc, London, UK), an EGFR-Her2 dual inhibitor, was performed in unscreened patients with platinum-sensitive recurrent ovarian cancer (Kimball et al, 2008).